A Phase 2 interventional study of ABvac40 and Placebo in Mild Cognitive Impairment and Alzheimer Disease, sponsored by Araclon Biotech S.L.. Completed at 23 sites in 4 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Araclon Biotech S.L. (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Cognitive Dysfunction with a site in Spain — 43 open to participants now, 60 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.
Among the 161 studies in Cognitive Dysfunction with a site in Spain, this one is the 47th largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2017, is one of 15 in phase 2, and was the 29th registered.
3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,122 are open to participants now.
Browse Cognitive Dysfunction studies →43 of the 161 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 70+
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 18+
Consorci Sanitari de Terrassa · Sites in Spain
Ages 65+ · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Universidad Complutense de Madrid · Sites in Spain
Ages 65–85
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 19 · Phase 3 16 · Phase 4 3
First in 2004; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 64 across 2,802 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 100 across the 126 interventional studies, 250 across the 35 observational. Of the 77 that completed or were terminated, 16 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 161 have an industry lead sponsor. The 10 most frequent:
This study is registered under Araclon Biotech S.L., one of the names counted as Grifols. Under that name alone:
Araclon Biotech S.L. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Grifols has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
15 of the studies in Cognitive Dysfunction with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07802392Consorci Sanitari de TerrassaImmersive Nature-Based Wellbeing Program in Older Adults With Cognitive Impairment | 2026-11 |
| NCT07793682Althaia Xarxa Assistencial Universitària de ManresaEarly Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke | 2026-11-25 |
| NCT06956794Consorci Sanitari de TerrassaMultimodal Training With Immersive Virtual Reality to Improve the Cognitive Health and Emotional Well-being of Older Women Living Alone | 2026-12-01 |
| NCT05289258Universidad de CórdobaUnified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments | 2026-12-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 161 studies in Cognitive Dysfunction with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide. The amyloid cascade hypothesis of AD proposes that amyloid-β (Aβ) peptide accumulation in the brain, caused by an imbalance between Aβ production and clearance, is the initiating factor of a cascade ultimately leading to dementia.
Aβ peptides are generated from sequential cleavage of the amyloid precursor protein (APP), including Aβ40 and Aβ42. Aβ40 is the predominant variant (90%) among the secreted Aβ forms and although Aβ42 is more hydrophobic and prone to aggregate, and Aβ42 oligomers are regarded to be the most neurotoxic species, Aβ40 can also produce highly toxic diffusible aggregates, which can be prevented in vitro by specific anti-Aβ40 antibodies.
Several studies have proposed that a high concentration of Aβ40 in the brain distinguishes patients with AD from those who have senile plaques but are cognitively normal, pointing to the importance of Aβ40 in the onset of dementia. In keeping with this, previous studies have demonstrated that specific anti-Aβ40 antibodies label NFTs in the entorhinal cortex and the hippocampus of AD brains, and that these do not co-localize with tau NFTs, suggesting the presence of degenerating neuronal populations filled with C-terminal fragments of Aβx-40. In addition, Aβ40 is the main component of amyloid deposition around cerebral arteries causing cerebral amyloid angiopathy (CAA), which has a prevalence of about 80-90% in patients with AD (for more information see Lacosta et al. Alzheimer's Research \& Therapy (2018) 10:12 DOI 10.1186/s13195-018-0340-8).
Considering those previous results suggesting that strategies targeting Aβ40 could represent novel disease-modifying therapies, we have developed ABvac40, the first active vaccine targeting the C-terminal end of the Aβ40 peptide.
The purpose of this Phase II study is to confirm in patients with a-MCI or vm-AD the level of safety and tolerability obtained in the ABvac40 Phase I clinical trial in patients with mm-AD. In addition, the study is aimed to better characterize the immune response elicited by ABvac40 and to explore its effects on AD biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject must meet all the following inclusion criteria:
Exclusion Criteria:
A subject meeting any of the following exclusion criteria is NOT eligible for participation in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
Biological: ABvac40
Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
Biological: Placebo
ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminum hydroxide as adjuvant.
Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminum hydroxide) without the conjugate.
Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA)
Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit.
Time frame: Part A (Baseline, and post-Baseline visits at Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Subject Discontinuations Due to TEAEs
Number of withdrawn subjects due to treatment-emergent adverse events (TEAEs) during the whole study.
Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Number of Subjects With Clinically Significant Abnormalities in Physical Examination
Clinically significant (CS) abnormalities in physical examination reported during the study.
Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Number of Subjects With Clinically Significant Abnormalities in Neurological Examination
Clinically significant (CS) abnormalities in neurological examination reported during the study.
Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Number of Subjects With Clinically Significant Abnormalities in Analytical Hematology
Clinically significant (CS) abnormalities in hematology parameters reported during the study.
Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Number of Subjects With Clinically Significant Abnormalities in Analytical Biochemistry
Clinically significant (CS) abnormalities in biochemistry parameters reported during the study.
Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Number of Subjects With Clinically Significant Abnormalities in Coagulation
Clinically significant (CS) abnormalities in coagulation parameters reported during the study.
Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Level of Anti-Aβ40 Antibodies in CSF
The change in levels of anti-Aβ40 antibodies in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Level of Anti-Aβ40 Antibodies in Plasma
The change in levels of anti-Aβ40 antibodies in plasma from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Level of Antibody-secreting Cells
The change in levels of antibody-secreting cells from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Level of Aβ40 Peptides in Plasma - ABtest-IA
The change in levels of anti-Aβ40 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Level of Aβ42 Peptides in Plasma - ABtest-IA
The change in levels of anti-Aβ42 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Level of Aβ40 Peptides in Plasma - ABtest-MS
The change in levels of anti-Aβ40 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Level of Aβ42 Peptides in Plasma - ABtest-MS
The change in levels of anti-Aβ42 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Cortical Fibrillary Amyloid Deposition Assessed by a-PET Scans
The change in amyloid-PET (a-PET) standard centiloid global cortical area (reference Pons) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Percentage of Change in Brain Volume
The percent change in brain volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, and Week 104A)
Percentage of Change in Hippocampal Volume
The percent change in right and left hippocampal volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, Week 104A)
Percentage of Change in Ventricular Volume
The percent change in ventricular volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, and Week 104A)
Level of Aβ42 Peptides in CSF
The change in levels of Aβ42 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Level of Aβ40 Peptides in CSF
The change in levels of Aβ40 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Aβ42/Aβ40 Ratio in CSF
The change in Aβ42/Aβ40 ratio in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Level of Total Tau in CSF
The change in levels of total Tau in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Level of p-Tau 181 in CSF
The change in levels of p-Tau 181 in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Level of Neurofilament Light in CSF
The change in levels of neurofilament light in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Level of Neurogranin in CSF
The change in levels of neurogranin in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Mini Mental State Examination (MMSE) Score
The change in MMSE score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. MMSE is an 11-question measure that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall, and language. MMSE score ranges: 0-30, with lower scores indicating worst cognition. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (baseline, and post-baseline at Week 24A, Week 50A, Week 77A, and Week 104A)
Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score
The change in CDR-SB score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. CDR-SB assesses 6 cognitive and functional domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, Personal Care. CDR-SB score ranges: 0-18. The higher scores mean a worst outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score
The change in RBANS total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. RBANS assesses 5 cognitive domains: Immediate Memory, Visuospatial/constructional, Language, Attention, Delayed Memory. Total score (range 40-160) sums the 5 domain scores. The higher scores mean a better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Alzheimer's Disease Cooperative Study - Activities of Daily Living, Mild Cognitive Impairment (ADCS-ADL MCI) Score
The change in ADCS-ADL MCI total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. ADCS-ADL MCI is a 24-item scale that includes 6 basic activities of daily living (ADL) items and 16 instrumental ADL items that provide a total score: 0-78, with a lower score indicating greater severity. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Trail Making Test (TMT) Scores
Change in TMT score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. TMT has 2 parts in which the patient connects 25 dots in order as quickly as possible. In TMT-A, targets are numbers 1-25; in TMT-B, targets are numbers 1-13 interleaved with letters A-L. Lower timings indicate better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Investigator Global Evaluation (IGE) Score
Change in IGE from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. IGE at baseline:1-Good general status;2-Slight deterioration;3-Moderate deterioration;4-Bad general status. IGE after baseline:1-Marked improvement;2-Moderate improvement;3-Slight improvement;4-No change;5-Slight worsening;6-Moderate worsening;7-Marked worsening. MMRM included IGE after baseline as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix is used. Following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly significantly associated with response measure (p \< 0.15).
Time frame: Part A (Week 24A, Week 50A, and Week 104A)
Columbia Suicide Severity Rating Scale
Subjects with suicidal ideation or suicidal behavior since last visit.
Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Overall Severity Index Score
Change in EQ-5D-5L overall severity index from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. EQ-5D-5L has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; rated: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
EuroQol 5 Dimensions 5 Levels - Visual Analogue Scale (EQ-5D-5L - VAS) Score
The change in EQ-5D-5L - VAS score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. VAS records the patient's self-rated health on a vertical scale, ranging from 100 = 'Best imaginable health state' down to 0 = 'Worst imaginable health state'. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
Time frame: Part A (Week 50A and Week 104A)
Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) - Sensitivity
Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit. Sensitivity analyses in the PP (Part A) analysis set.
Time frame: Part A (Baseline, and post-Baseline visits at Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
A total of 23 centers in Spain (n=18), France (n=3), Italy (n=1) and Sweden (n=1) recruited subjects in this study. The subjects' recruitment was competitive until the required number of subjects was completed.
| Milestone | Placebo Arm Part A/ABvac40 Arm Part B | ABvac40 Arm Part A/Placebo+Booster Arm Part B |
|---|---|---|
| Started | 62 | 62 |
| Completed | 53 | 55 |
| Not completed | 9 | 7 |
| Withdrew: Adverse event, serious fatal | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event, non-fatal | 3 | 1 |
| Withdrew: Patient heath status | 0 | 1 |
| Withdrew: Patient/caregiver's decision | 3 | 3 |
| Milestone | Placebo Arm Part A/ABvac40 Arm Part B | ABvac40 Arm Part A/Placebo+Booster Arm Part B |
|---|---|---|
| Started | 37 | 40 |
| Completed | 33 | 38 |
| Not completed | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event, non-fatal | 0 | 1 |
| Withdrew: Patient/caregiver's decision | 3 | 0 |
Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit.
| OD | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) | 0.12 ± 0.21 | 3.27 ± 0.75 |
Number of withdrawn subjects due to treatment-emergent adverse events (TEAEs) during the whole study.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Subject Discontinuations Due to TEAEs | 4 | 2 | 0 | 1 |
Clinically significant (CS) abnormalities in physical examination reported during the study.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormalities in Physical Examination | 4 | 1 | 4 | 2 |
Clinically significant (CS) abnormalities in neurological examination reported during the study.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormalities in Neurological Examination | 6 | 5 | 2 | 1 |
Clinically significant (CS) abnormalities in hematology parameters reported during the study.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormalities in Analytical Hematology | 5 | 4 | 0 | 6 |
Clinically significant (CS) abnormalities in biochemistry parameters reported during the study.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormalities in Analytical Biochemistry | 12 | 5 | 6 | 6 |
Clinically significant (CS) abnormalities in coagulation parameters reported during the study.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormalities in Coagulation | 4 | 1 | 3 | 2 |
The change in levels of anti-Aβ40 antibodies in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| ng/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 0.1654 ± 3.86502 | 30.1826 ± 3.90756 |
| Week 104A | 0.2014 ± 0.36753 | 1.2437 ± 0.41902 |
The change in levels of anti-Aβ40 antibodies in plasma from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| μg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 2A | 1.5580 ± 4.22100 | 1.5112 ± 4.40221 |
| Week 6A | 1.5580 ± 4.22100 | 13.7052 ± 4.44801 |
| Week 10A | 1.6172 ± 4.24276 | 44.3187 ± 4.41509 |
| Week 14A | 1.5479 ± 4.24276 | 62.1946 ± 4.43781 |
| Week 18A | 1.5789 ± 4.30746 | 69.8861 ± 4.43781 |
| Week 24A | 1.5926 ± 4.26432 | 39.9483 ± 4.44151 |
| Week 40A | 1.6027 ± 4.33264 | 14.6139 ± 4.48526 |
| Week 44A | 1.5463 ± 4.35267 | 57.5771 ± 4.48568 |
| Week 50A | 1.5993 ± 4.35363 | 33.5366 ± 4.51418 |
| Week 77A | 1.5232 ± 4.37735 | 10.8197 ± 4.57100 |
| Week 104A | 1.7400 ± 5.57743 | 10.8365 ± 5.82224 |
The change in levels of antibody-secreting cells from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| SFU/0.5x10^6 PBMCs | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 2A | -0.4596 ± 0.37670 | 0.1943 ± 0.34478 |
| Week 6A | -0.1172 ± 0.72366 | 2.3198 ± 0.67598 |
| Week 10A | 0.2730 ± 0.78308 | 4.0542 ± 0.72897 |
| Week 14A | -0.1929 ± 1.44746 | 7.5160 ± 1.36639 |
| Week 18A | 0.2480 ± 1.02814 | 6.9016 ± 0.93531 |
| Week 24A | 0.4532 ± 0.73744 | 3.6179 ± 0.67779 |
| Week 40A | -0.5655 ± 0.42886 | 1.2534 ± 0.38540 |
| Week 44A | -1.2538 ± 2.45677 | 10.1860 ± 2.23291 |
| Week 50A | -0.3314 ± 1.06961 | 4.6143 ± 1.00245 |
| Week 77A | -0.4495 ± 0.52099 | 1.8385 ± 0.47208 |
| Week 104A | 0.1758 ± 0.41889 | 0.3735 ± 0.41451 |
The change in levels of anti-Aβ40 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 2A | 3.8381 ± 2.15040 | 4.0604 ± 2.15734 |
| Week 6A | 4.5019 ± 2.57561 | 8.9863 ± 2.56744 |
| Week 10A | 5.5195 ± 3.38710 | -2.7073 ± 3.37532 |
| Week 14A | 6.0407 ± 4.73576 | -9.9564 ± 4.72351 |
| Week 18A | 8.9690 ± 4.67231 | -12.7882 ± 4.63367 |
| Week 24A | 7.6033 ± 4.05399 | -30.0419 ± 4.02351 |
| Week 40A | 5.9903 ± 4.72341 | -42.6835 ± 4.64278 |
| Week 44A | 8.6825 ± 5.47731 | -36.1069 ± 5.37898 |
| Week 50A | 7.7553 ± 5.58033 | -36.3509 ± 5.47307 |
| Week 77A | 11.2896 ± 5.12501 | -31.1947 ± 5.03820 |
| Week 104A | 9.1909 ± 7.62291 | -15.8591 ± 7.65813 |
The change in levels of anti-Aβ42 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 2A | 0.6745 ± 0.47690 | 0.3868 ± 0.47126 |
| Week 6A | 1.2776 ± 0.77358 | 1.6248 ± 0.76131 |
| Week 10A | 1.2091 ± 0.88576 | 2.1331 ± 0.87167 |
| Week 14A | 1.6433 ± 0.73975 | 1.0209 ± 0.72987 |
| Week 18A | 1.9821 ± 0.55465 | 1.2815 ± 0.54507 |
| Week 24A | 2.8599 ± 0.72452 | 1.6125 ± 0.71101 |
| Week 40A | 2.0361 ± 0.84268 | -1.2781 ± 0.81992 |
| Week 44A | 1.7850 ± 1.00896 | -0.9785 ± 0.98520 |
| Week 50A | 2.6958 ± 1.24460 | 0.5563 ± 1.21767 |
| Week 77A | 2.9304 ± 1.15392 | 0.9045 ± 1.13274 |
| Week 104A | 0.8402 ± 1.36427 | 0.5027 ± 1.34946 |
The change in levels of anti-Aβ40 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 2A | 15.0554 ± 86.19364 | 7.2235 ± 87.23687 |
| Week 6A | 12.9981 ± 86.19364 | 26.8351 ± 87.24290 |
| Week 10A | 10.8314 ± 86.57079 | 123.0016 ± 87.42725 |
| Week 14A | 10.1449 ± 86.57079 | 277.9974 ± 87.75818 |
| Week 18A | 10.1987 ± 87.66045 | 397.6406 ± 88.10607 |
| Week 24A | 31.0861 ± 86.93514 | 453.1893 ± 88.16061 |
| Week 40A | -26.9761 ± 88.54373 | 377.7762 ± 88.44661 |
| Week 44A | -28.4349 ± 88.50690 | 846.1633 ± 88.82717 |
| Week 50A | -34.2153 ± 88.91637 | 628.9483 ± 88.88059 |
| Week 77A | -30.9656 ± 89.32946 | 155.5480 ± 89.69327 |
| Week 104A | -37.3585 ± 110.48329 | 85.9804 ± 113.05734 |
The change in levels of anti-Aβ42 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 2A | -0.2211 ± 1.22162 | -0.0175 ± 1.22543 |
| Week 6A | -0.2339 ± 1.32582 | 1.7627 ± 1.32847 |
| Week 10A | -1.1074 ± 1.32226 | 0.8282 ± 1.32090 |
| Week 14A | 0.0854 ± 1.14369 | 0.4418 ± 1.15082 |
| Week 18A | 0.5632 ± 1.51032 | -0.9906 ± 1.49756 |
| Week 24A | -0.1341 ± 1.37466 | -1.6456 ± 1.37921 |
| Week 40A | 2.8714 ± 1.70845 | 3.3146 ± 1.68116 |
| Week 44A | 1.5116 ± 1.51817 | 1.9216 ± 1.49840 |
| Week 50A | 0.1124 ± 1.48787 | 2.6909 ± 1.46207 |
| Week 77A | 1.3886 ± 1.61156 | 4.6804 ± 1.58811 |
| Week 104A | 4.6921 ± 2.18829 | 2.6075 ± 2.19973 |
The change in amyloid-PET (a-PET) standard centiloid global cortical area (reference Pons) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| Centiloids | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 1.411 ± 1.1203 | 3.561 ± 1.0918 |
| Week 104A | 4.461 ± 1.3841 | 1.241 ± 1.5403 |
The percent change in brain volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| percent change | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | -1.39 ± 0.157 | -1.40 ± 0.165 |
| Week 50A | -2.05 ± 0.175 | -1.75 ± 0.187 |
| Week 104A | -4.16 ± 0.470 | -3.11 ± 0.412 |
The percent change in right and left hippocampal volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| percent change | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A - left | -1.63 ± 0.450 | -2.17 ± 0.449 |
| Week 50A - left | -4.16 ± 0.582 | -4.26 ± 0.568 |
| Week 104A - left | -7.17 ± 1.055 | -8.18 ± 0.962 |
| Week 24A - right | -1.37 ± 0.442 | -1.44 ± 0.439 |
| Week 50A - right | -3.34 ± 0.513 | -3.23 ± 0.506 |
| Week 104A - right | -6.37 ± 1.001 | -6.49 ± 0.901 |
The percent change in ventricular volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| percent change | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | 5.30 ± 0.584 | 5.94 ± 0.573 |
| Week 50A | 10.63 ± 0.809 | 10.21 ± 0.819 |
| Week 104A | 22.51 ± 1.887 | 21.26 ± 1.848 |
The change in levels of Aβ42 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 29.0 ± 19.40 | -2.0 ± 19.79 |
| Week 104A | -15.3 ± 22.51 | 4.0 ± 25.82 |
The change in levels of Aβ40 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | -62.3 ± 173.57 | -141.8 ± 180.07 |
| Week 104A | -652.4 ± 227.08 | -192.5 ± 260.67 |
The change in Aβ42/Aβ40 ratio in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| Ratio | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 0.0007 ± 0.00134 | 0.0009 ± 0.00129 |
| Week 104A | 0.0018 ± 0.00182 | 0.0021 ± 0.00204 |
The change in levels of total Tau in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 26.2 ± 12.08 | 17.8 ± 12.40 |
| Week 104A | 27.6 ± 14.25 | 15.9 ± 16.43 |
The change in levels of p-Tau 181 in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 2.84 ± 1.664 | 3.14 ± 1.696 |
| Week 104A | 1.97 ± 2.386 | 0.80 ± 2.646 |
The change in levels of neurofilament light in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | 59.36 ± 76.513 | 181.20 ± 78.606 |
| Week 104A | 317.11 ± 190.948 | 276.14 ± 216.781 |
The change in levels of neurogranin in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| pg/mL | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | -4.69 ± 8.023 | -5.93 ± 8.328 |
| Week 104A | -34.97 ± 13.533 | -31.13 ± 15.571 |
The change in MMSE score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. MMSE is an 11-question measure that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall, and language. MMSE score ranges: 0-30, with lower scores indicating worst cognition. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | -2.15 ± 0.422 | -2.24 ± 0.420 |
| Week 50A | -3.64 ± 0.465 | -2.65 ± 0.460 |
| Week 77A | -4.58 ± 0.628 | -4.15 ± 0.621 |
| Week 104A | -5.98 ± 0.816 | -4.97 ± 0.816 |
The change in CDR-SB score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. CDR-SB assesses 6 cognitive and functional domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, Personal Care. CDR-SB score ranges: 0-18. The higher scores mean a worst outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | 0.75 ± 0.152 | 0.73 ± 0.156 |
| Week 50A | 1.41 ± 0.222 | 1.36 ± 0.221 |
| Week 77A | 2.12 ± 0.328 | 2.05 ± 0.325 |
| Week 104A | 3.21 ± 0.463 | 2.90 ± 0.462 |
The change in RBANS total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. RBANS assesses 5 cognitive domains: Immediate Memory, Visuospatial/constructional, Language, Attention, Delayed Memory. Total score (range 40-160) sums the 5 domain scores. The higher scores mean a better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | -1.30 ± 1.009 | -2.10 ± 1.022 |
| Week 50A | -5.45 ± 1.076 | -5.56 ± 1.077 |
| Week 77A | -4.71 ± 1.273 | -2.66 ± 1.255 |
| Week 104A | -3.17 ± 1.798 | -1.33 ± 1.793 |
The change in ADCS-ADL MCI total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. ADCS-ADL MCI is a 24-item scale that includes 6 basic activities of daily living (ADL) items and 16 instrumental ADL items that provide a total score: 0-78, with a lower score indicating greater severity. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | -0.99 ± 0.834 | -2.08 ± 0.844 |
| Week 50A | -4.15 ± 1.124 | -3.78 ± 1.112 |
| Week 77A | -6.33 ± 1.399 | -6.54 ± 1.380 |
| Week 104A | -9.87 ± 2.002 | -10.02 ± 1.982 |
Change in TMT score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. TMT has 2 parts in which the patient connects 25 dots in order as quickly as possible. In TMT-A, targets are numbers 1-25; in TMT-B, targets are numbers 1-13 interleaved with letters A-L. Lower timings indicate better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| seconds | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A - Trail A | 0.54 ± 2.960 | -0.59 ± 2.939 |
| Week 50A - Trail A | 11.34 ± 4.186 | 3.59 ± 4.023 |
| Week 77A - Trail A | 17.42 ± 4.669 | 2.79 ± 4.425 |
| Week 104A - Trail A | 20.09 ± 7.253 | 9.24 ± 6.967 |
| Week 24A - Trail B | 5.43 ± 8.102 | -8.47 ± 8.464 |
| Week 50A - Trail B | 18.83 ± 8.503 | 18.43 ± 9.122 |
| Week 77A - Trail B | 17.13 ± 8.680 | 2.38 ± 9.762 |
| Week 104A - Trail B | 20.81 ± 10.715 | -4.64 ± 11.206 |
Change in IGE from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. IGE at baseline:1-Good general status;2-Slight deterioration;3-Moderate deterioration;4-Bad general status. IGE after baseline:1-Marked improvement;2-Moderate improvement;3-Slight improvement;4-No change;5-Slight worsening;6-Moderate worsening;7-Marked worsening. MMRM included IGE after baseline as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix is used. Following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly significantly associated with response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A | 4.02 ± 0.075 | 4.07 ± 0.077 |
| Week 50A | 4.26 ± 0.101 | 4.21 ± 0.101 |
| Week 104A | 4.55 ± 0.180 | 4.45 ± 0.184 |
Subjects with suicidal ideation or suicidal behavior since last visit.
| Participants | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 24A - suicidal ideation | 1 | 1 |
| Week 24A - suicidal behavior | 0 | 0 |
| Week 50A - suicidal ideation | 1 | 2 |
| Week 50A - suicidal behavior | 0 | 0 |
| Week 77A - suicidal ideation | 1 | 4 |
| Week 77A - suicidal behavior | 0 | 0 |
| Week 104A - suicidal ideation | 0 | 0 |
| Week 104A - suicidal behavior | 0 | 0 |
Change in EQ-5D-5L overall severity index from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. EQ-5D-5L has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; rated: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | -0.99 ± 1.204 | -2.71 ± 1.196 |
| Week 104A | -3.06 ± 1.740 | -0.92 ± 1.725 |
The change in EQ-5D-5L - VAS score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. VAS records the patient's self-rated health on a vertical scale, ranging from 100 = 'Best imaginable health state' down to 0 = 'Worst imaginable health state'. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).
| score on a scale | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Week 50A | -4.77 ± 2.355 | -4.92 ± 2.323 |
| Week 104A | -5.22 ± 3.114 | -1.08 ± 3.093 |
Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit. Sensitivity analyses in the PP (Part A) analysis set.
| OD | Placebo Arm Part A | ABvac40 Arm Part A |
|---|---|---|
| Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) - Sensitivity | 0.10 ± 0.13 | 3.29 ± 0.67 |
Collected over Whole study duration (Part A+Part B; up to 42 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Arm Part A | 1/60 (1.7%) | 16/60 (26.7%) | 53/60 (88.3%) |
| ABvac40 Arm Part A | 1/64 (1.6%) | 17/64 (26.6%) | 57/64 (89.1%) |
| ABvac40 Arm Part B | 0/37 (0%) | 6/37 (16.2%) | 30/37 (81.1%) |
| Placebo+Booster Arm Part B | 0/40 (0%) | 2/40 (5%) | 30/40 (75%) |
| Event | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Amyloid related imaging abnormalitiesNervous system disorders | 9/60 | 8/64 | 1/37 | 0/40 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/60 | 3/64 | 0/37 | 0/40 |
| Femur fractureInjury, poisoning and procedural complications | 0/60 | 2/64 | 0/37 | 0/40 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/60 | 0/64 | 1/37 | 0/40 |
| Venous thrombosis limbVascular disorders | 0/60 | 0/64 | 1/37 | 0/40 |
| Acute myocardial infarctionCardiac disorders | 0/60 | 0/64 | 1/37 | 0/40 |
| Atrial fibrillationCardiac disorders | 1/60 | 0/64 | 1/37 | 0/40 |
| Atrioventricular block completeCardiac disorders | 0/60 | 0/64 | 1/37 | 0/40 |
| Lacunar infarctionNervous system disorders | 0/60 | 0/64 | 0/37 | 1/40 |
| Coronavirus infectionInfections and infestations | 0/60 | 0/64 | 0/37 | 1/40 |
| Event | Placebo Arm Part A | ABvac40 Arm Part A | ABvac40 Arm Part B | Placebo+Booster Arm Part B |
|---|---|---|---|---|
| Coronavirus infectionInfections and infestations | 1/60 | 4/64 | 6/37 | 9/40 |
| Urinary tract infectionInfections and infestations | 3/60 | 11/64 | 5/37 | 4/40 |
| ErythemaSkin and subcutaneous tissue disorders | 7/60 | 10/64 | 3/37 | 0/40 |
| FallInjury, poisoning and procedural complications | 4/60 | 9/64 | 0/37 | 4/40 |
| HeadacheNervous system disorders | 7/60 | 5/64 | 3/37 | 3/40 |
| Injection site reactionGeneral disorders | 4/60 | 4/64 | 4/37 | 3/40 |
| Peripheral swellingGeneral disorders | 1/60 | 1/64 | 4/37 | 1/40 |
| HypertensionVascular disorders | 6/60 | 3/64 | 0/37 | 0/40 |
| Injection site erythemaGeneral disorders | 4/60 | 6/64 | 3/37 | 1/40 |
| PruritusSkin and subcutaneous tissue disorders | 1/60 | 2/64 | 3/37 | 0/40 |
Subjects who received Placebo or ABvac40 during Part A.
| Age, Continuous(years) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| Mean | 70.1 ± 5.49 | 70.6 ± 5.95 | 70.4 ± 5.71 |
| Sex: Female, Male(Participants) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| Female | 36 | 38 | 74 |
| Male | 26 | 24 | 50 |
| Race/Ethnicity, Customized(Participants) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| Asian/Pacific islander | 0 | 0 | 0 |
| Black | 0 | 0 | 0 |
| Caucasian | 60 | 58 | 118 |
| Other | 1 | 1 | 2 |
| Missing | 1 | 3 | 4 |
| Study Disease(Participants) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| amnestic Mild Cognitive Impairment (a-MCI) | 42 | 38 | 80 |
| Very Mild Alzheimer's disease (VMAD) | 20 | 24 | 44 |
| Amyloid-positron Emission Tomography (a-PET) Status(Participants) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| Positive | 45 | 47 | 92 |
| Negative | 17 | 15 | 32 |
| Apolipoprotein E (ApoE) Status(Participants) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| Noncarriers: E2/E2 and E2/E3, E3/E3 | 24 | 24 | 48 |
| Carriers (Heterozygous: E2/E4, E3/E4) | 33 | 29 | 62 |
| Carriers (Homozygous: E4/E4) | 5 | 9 | 14 |
| Time from Disease Diagnosis to Informed Consent(months) | Placebo Arm Part A | ABvac40 Arm Part A | Total |
|---|---|---|---|
| Mean | 14.48 ± 15.81 | 14.68 ± 13.71 | 14.58 ± 14.74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Mar 2023, 63 months.
Results were first posted in Feb 2025, 1 year 10 months after primary completion.
Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's 63 months is above that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.